Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. The company supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). The company supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The company supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.
Follow-Up Questions
Hikma Pharmaceuticals PLC 'in CEO'su kimdir?
Mr. Riad Mishlawi 2011 'den beri şirketle birlikte olan Hikma Pharmaceuticals PLC 'in Chief Executive Officer 'ıdır.
HKMPY hissesinin fiyat performansı nasıl?
HKMPY 'in mevcut fiyatı $47.47 'dir, son işlem günde 0% decreased etti.
Hikma Pharmaceuticals PLC için ana iş temaları veya sektörler nelerdir?
Hikma Pharmaceuticals PLC Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 15 analist Hikma Pharmaceuticals PLC için analist derecelendirmeleri gerçekleştirdi, bunlar 6 güçlü al, 10 al, 4 tut, 0 sat ve 6 güçlü sat içermektedir
